BACE1 and Alzheimer disease: Several lines of evidence have shown that Sirt2 inhibitor (AGK-2 and AK-7) injection in AD-like mouse models decreased Aβ generation by reducing BACE1 levels, thus leading to an amelioration of cognitive impairment [26, 55].